
Eleven Biotherapeutics (EBIO) P/E Ratio
P/E Ratio as of Dec 3, 2025: 0.30
Average0.2000
Median0.2600
Minimum-0.0400
Maximum0.3400
0.30
0.34 (850.00%)past month
The P/E ratio for Eleven Biotherapeutics (EBIO) is 0.30 as of Dec 3, 2025. This represents a decrease of -266.67% compared to its 12-month average P/E ratio of -0.18. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Eleven Biotherapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Eleven Biotherapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Eleven Biotherapeutics to industry peers.
Eleven Biotherapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Eleven Biotherapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Eleven Biotherapeutics to industry peers.
Eleven Biotherapeutics (EBIO) P/E Ratio Insights
See Eleven Biotherapeutics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Eleven Biotherapeutics (EBIO)
Order type
Buy in
Order amount
Est. shares
0 shares
Eleven Biotherapeutics (EBIO) P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Dec 1, 2025 | $0.0591 | 0.31 |
| Nov 3, 2025 | $0.05 | -0.04 |
| Oct 1, 2025 | $0.256 | -0.22 |
| Sep 2, 2025 | $0.44 | -0.37 |
| Aug 1, 2025 | $0.3115 | -0.26 |
| Jul 1, 2025 | $0.4049 | -0.33 |
| Jun 2, 2025 | $0.20 | -0.16 |
| May 1, 2025 | $0.2019 | -0.14 |
| Apr 1, 2025 | $0.2305 | -0.16 |
| Mar 3, 2025 | $0.4004 | -0.26 |
| Feb 3, 2025 | $0.457 | -0.29 |
| Jan 2, 2025 | $0.4401 | -0.28 |
Eleven Biotherapeutics (EBIO) End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2025 | 0.30 | -211.11% |
| 2024 | -0.27 | -65.82% |
| 2023 | -0.79 | -73.93% |
| 2022 | -3.03 | +309.46% |
| 2021 | -0.74 | 0.00% |
| 2020 | -0.74 | — |
FAQs About Eleven Biotherapeutics (EBIO) P/E ratio
The latest P/E ratio of Eleven Biotherapeutics (EBIO) is 0.30, as of Dec 3, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Eleven Biotherapeutics’s last 12-month average P/E ratio is -0.18, compared to its current P/E ratio of 0.30. This reflects a decrease of -266.67%.
Eleven Biotherapeutics’s current P/E ratio of 0.30 is lower than its last 12-month average P/E of -0.18. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Eleven Biotherapeutics’s average P/E ratio over the last 3 years is -1. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Eleven Biotherapeutics’s average P/E ratio over the last 5 years is -0.84. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.